SDGR Technical Analysis & Stock Price Forecast
The technical analysis for Schrodinger Inc (SDGR) indicates a "Strong Sell" consensus as of April 2, 2026. This is based on 10 technical signals, with 7 indicating a sell and 3 indicating a buy, and is further supported by moving averages and oscillator readings like MACD and RSI. The stock is currently trading below its 60-day and 200-day moving averages, positioned between immediate resistance at $12.276 and strong support at $10.841.
Avoiding Lag: Real-Time Signals in (SDGR) Movement
This article analyzes Schrodinger Inc. (SDGR) with weak sentiment across all horizons, supporting a short bias. It highlights a mid-channel oscillation pattern and an exceptional 78.7:1 risk-reward setup targeting a 21.7% gain versus 0.3% risk. The piece outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing specific entry, target, and stop-loss levels.
Schrodinger Inc Stock: Physics-Based Computing Leader in Drug Discovery and Materials Science for In
Schrodinger Inc. (ISIN: US80655G1067) uses physics-based computation to revolutionize drug discovery and materials science, offering a platform that enhances molecular modeling accuracy and reduces R&D costs. The company's hybrid physics-AI model and diversified revenue streams from software licensing, collaborative projects, and royalties position it as a key player in the biotechnology and materials sectors. Investors should note its NASDAQ listing (SDGR) and its role in accelerating innovation in critical areas like oncology and renewable energy, despite potential risks like client concentration and intense competition.
Schrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Hold" by Brokerages
Schrodinger, Inc. (NASDAQ:SDGR) has received an average "Hold" recommendation from nine brokerages, with an average 1-year price target of $21.13. Despite reporting strong quarterly EPS of $0.44 against a consensus of -$0.13 and revenue of $87.24 million, the company remains unprofitable with a negative net margin. Insiders and institutions hold significant stakes, with the CEO recently selling shares.
Vanguard disaggregates holdings; SDGR filing shows 0 shares (SDGR)
The Vanguard Group filed an amended Schedule 13G/A for Schrodinger Inc. (SDGR), reporting 0 shares beneficially owned, representing 0% of common stock. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. This is an administrative redistribution of reporting responsibilities rather than a sale of shares, with Vanguard Group no longer deemed to have beneficial ownership over securities held by these subsidiaries.
Schrödinger Discontinues Clinical Program After Two Patient Deaths
Schrödinger (SDGR) has discontinued its MALT1 inhibitor clinical program (SGR-1505) following the deaths of two patients in its Phase 1 trial. The company immediately paused enrollment and dosing after the serious adverse events were reported. Despite the discontinuation, Schrödinger stated it has several promising oncology programs in its pipeline set to enter clinical trials.
Tudor Investment Corp ET AL Has $6.75 Million Position in Schrodinger, Inc. $SDGR
Tudor Investment Corp ET AL significantly increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 2,530.6% during the third quarter, now owning 336,379 shares valued at approximately $6.75 million. Despite beating quarterly earnings and revenue expectations, Schrodinger remains unprofitable with negative margins, holding an average analyst rating of "Hold" and a price target of $21.13. Recent insider selling has occurred, but institutional investors hold a substantial 79.05% of the stock.
Schrödinger (Nasdaq:SDGR) - Stock Analysis
This Simply Wall St stock analysis provides an overview of Schrödinger (SDGR), a company developing a physics-based computational platform for drug discovery and materials applications. The report covers the company's valuation, future growth prospects, past performance, financial health, and recent news, noting its current undervaluation and projected revenue growth. Several community narratives discuss the potential impacts of AI adoption, clinical advancements, and market competition on SDGR's future.
Discipline and Rules-Based Execution in SDGR Response
This article provides an in-depth analysis of Schrodinger Inc. (NASDAQ: SDGR) using AI models to suggest trading strategies. It highlights a weak near-term sentiment with potential resumption of long-term weakness, yet identifies an exceptional risk-reward setup. The analysis includes position trading, momentum breakout, and risk-hedging strategies, alongside multi-timeframe signal analysis for various holding periods.
Schrödinger (SDGR) Morgan Stanley 22nd Annual Global Healthcare Conference Summary
Schrödinger (SDGR) presented at the Morgan Stanley 22nd Annual Global Healthcare Conference, highlighting the resilience of their software business against macro trends and the early stages of industry-wide adoption. The company emphasized its competitive advantage through proprietary physics-based training sets and expressed strong confidence in its 2024 financial outlook, with revenue expected to be heavily weighted towards Q4. Growth drivers include multi-parameter optimization, advances in protein structure determination, and a "fear of missing out" among pharma companies.
Schrodinger downgraded at Citi after clinical program exit
Schrodinger (SDGR) has been downgraded to Neutral from Buy at Citi due to the discontinuation of its clinical program SGR-1505. This decision followed a pre-planned interim analysis, leading to increased risk for the company's remaining pipeline and a reassessment of its valuation. Citi has also lowered its price target for Schrodinger to $29 from $35.
Schrodinger downgraded at Citi after clinical program exit
NULL
Schrödinger updates 2025 software growth guidance to 8%-13% amid pharma scale-up delays and operational efficiency focus
Schrödinger (SDGR) has revised its 2025 software revenue growth guidance to 8%-13%, down from the previous 15%-20%. This adjustment is attributed to delays in pharmaceutical and biotech customers scaling up their discovery programs, alongside Schrödinger's internal focus on operational efficiency instead of aggressive sales force expansion. Despite these revisions, the company maintains its full-year 2024 total revenue guidance of $200 million-$220 million and software revenue guidance of 15%-18% growth.
Schrödinger updates 2025 software growth guidance to 8%-13% amid pharma scale-up delays and operational efficiency focus
Schrödinger has updated its 2025 software growth guidance to 8%-13%, down from the previous 15%-20%. This adjustment is attributed to delays in pharmaceutical scale-up and a focus on operational efficiency. The company aims to optimize its business model and strategically reallocate resources.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. reported inducement grants made on March 14, 2026, to three newly hired employees, consisting of non-statutory stock options and restricted stock units (RSUs). These grants were approved by the compensation committee and made as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4), with specific vesting schedules over four years. The grants are part of the company's 2021 Inducement Equity Incentive Plan.
SDGR: Analyst Michael Yee of UBS Lowers Price Target to $13, Maintains Neutral Rating | SDGR Stock News
UBS analyst Michael Yee has lowered the price target for Schrodinger (SDGR) to $13 from $18, while maintaining a Neutral rating. This adjustment reflects a 27.78% decrease and follows a trend of revised price targets from various analysts for the healthcare software company. Despite the downward revision, the average target price from 9 analysts is $23.11, implying an 85.78% upside from the current price, with an "Outperform" consensus recommendation.
SDGR: Analyst Michael Yee of UBS Lowers Price Target to $13, Maintains Neutral Rating | SDGR Stock News
UBS analyst Michael Yee has lowered the price target for Schrodinger (SDGR) to $13.00 from $18.00 while maintaining a Neutral rating. This adjustment reflects a 27.78% decrease and follows a trend of revised price targets from various analysts in recent months. Schrodinger is a healthcare-based software company specializing in drug discovery solutions, with its Software segment generating the majority of its revenue primarily from the United States.
UBS Group Cuts Schrodinger (NASDAQ:SDGR) Price Target to $13.00
UBS Group has reduced its price target for Schrodinger (NASDAQ:SDGR) to $13.00 from $18.00 while maintaining a "neutral" rating, indicating a potential upside of approximately 4%. Despite beating recent EPS and revenue estimates, Schrodinger remains unprofitable, and insiders have been selling shares. The average analyst target price for the stock is $21.13, with a mixed consensus of "Hold."
SDGR: Strategic shift to hosted software, AI integration, and new products drive growth and industry impact
Schrodinger, Inc. (SDGR) is focusing on a strategic shift to hosted software contracts, AI integration, and new products like Predictive Tox for early toxicity prediction. These initiatives, along with an improved funding environment, are expected to drive growth and foster industry partnerships. This information was highlighted at the 2026 KeyBanc Capital Markets Healthcare Forum.
Schrödinger slides after early-stage trial data for cancer therapy
Schrödinger's shares fell following the release of early-stage trial data for its cancer therapy, SGR-1505. The data, presented at the American Association for Cancer Research (AACR) conference, showed that 104 patients experienced side effects, with some severe, though the company stated no dose-limiting toxicities were observed. Despite the side effects, the company reported that 20% of patients showed tumor shrinkage, which it considers promising given the heavily pretreated patient population.
Schrödinger slides after early-stage trial data for cancer therapy
Schrödinger's stock slid after the release of early-stage trial data for its cancer therapy, SGR-1505. While the drug showed initial signs of anti-tumor activity and was generally well-tolerated, investors reacted negatively to the preliminary results, causing the stock to tumble by over 16%.
Do Options Traders Know Something About Schrodinger Stock We Don't?
This article examines unusual options trading activity for Schrodinger (SDGR) and discusses what this might imply for the stock's future movement. It notes a high institutional ownership and suggests that monitoring options trends could provide insights into potential stock shifts.
Schrödinger Promotes Therese Abrams to Principal Accounting Officer
Schrödinger, Inc. has appointed Therese Abrams as its Principal Accounting Officer, succeeding Jenny Herman. Abrams, who has been with Schrödinger since 2013, brings extensive financial experience and will ensure continuity in financial reporting. The company's stock (SDGR) currently holds a Neutral rating from TipRanks’ AI Analyst, Spark, citing inconsistent financial performance and a bearish technical trend, offset partly by strategic clarity and cash flow improvements.
Schrödinger (NASDAQ: SDGR) appoints Therese Abrams as principal accounting officer
Schrödinger, Inc. (NASDAQ: SDGR) has appointed Therese Abrams as its principal accounting officer, effective March 8, 2026. Ms. Abrams previously served as the company's Vice President, Corporate Controller since July 2025 and has a long history in finance and revenue roles at Schrödinger and other companies. Former Chief Accounting Officer Jenny Herman transitioned from her role on March 6, 2026, and will remain with the company through April 10, 2026, to facilitate a smooth transition.
Schrödinger at Leerink Conference: Strategic Growth Amid Transition
Schrödinger Inc. (NASDAQ:SDGR) discussed its strategic shift towards using Annual Contract Value (ACV) as a primary performance metric at the Leerink Global Healthcare Conference 2026. The company anticipates a revenue dip in 2026 due to this transition to hosted contracts but projects 10-15% annual ACV growth and aims for profitability by 2028. Key focus areas include platform innovation, increased ownership in co-founded companies, and growth in materials science, while firmly stating AI models are not a threat to its proprietary physics-based software.
Jain Rachit, Schrodinger CFO, sells $21k in SDGR stock By Investing.com
Schrodinger, Inc.'s CFO, Jain Rachit, sold 1,631 shares of common stock for approximately $21,033 on March 5, 2026, as part of a pre-arranged trading plan to cover tax obligations. Following this transaction, Jain retains 52,596 shares, including unvested Restricted Stock Units. The sale occurred amidst stock volatility, a week after the company reported strong Q4 and full-year 2025 earnings which exceeded revenue expectations.
SDGR: Transition to ACV, new product launches, and materials science drive growth outlook
Schrodinger, Inc. (SDGR) is focusing on a transition to Annual Contract Value (ACV) for better revenue predictability. The company plans to drive growth through new product launches, such as predictive toxicology modules, and sees long-term potential in materials science. This outlook is based on insights from the Leerink Global Healthcare Conference 2026.
Behavioral Patterns of SDGR and Institutional Flows
This article analyzes Schrodinger Inc. (NASDAQ: SDGR) using AI models to identify behavioral patterns and institutional flows. It highlights a near- and mid-term strong sentiment with a mid-channel oscillation pattern, suggesting a significant risk-reward setup. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis and support/resistance levels.
Ramy Farid Sells 3,661 Shares of Schrodinger (NASDAQ:SDGR) Stock
Schrodinger (NASDAQ:SDGR) CEO Ramy Farid sold 3,661 shares of the company's stock on March 5th, totaling over $47,000. This sale, along with sales from other executives, has reduced insider holdings, potentially signaling near-term selling pressure. Despite beating quarterly EPS and revenue estimates, the company remains unprofitable and carries an average "Hold" analyst rating.
Schrodinger (NASDAQ:SDGR) EVP Yvonne Tran Sells 1,094 Shares
Schrodinger's EVP Yvonne Tran sold 1,094 shares of SDGR stock on March 5th for approximately $14,101, reducing her stake by 2.03%. This sale is part of a cluster of insider sales from March 4-6, including the CEO and CFO, which has raised concerns and coincided with a 2.2% intraday decline in the stock. Despite reporting an EPS beat and exceeding revenue estimates, Schrodinger remains unprofitable, and analysts currently hold a consensus "Hold" rating with a $21.75 price target for the stock.
Jain Rachit, Schrodinger CFO, sells $21k in SDGR stock By Investing.com
Schrodinger CFO Jain Rachit sold 1,631 shares of SDGR stock worth $21,033 on March 5, 2026, as part of a pre-arranged trading plan to cover tax obligations. Following the sale, Jain directly owns 52,596 shares, including unvested RSUs. This comes as the company recently reported strong Q4 and full-year 2025 earnings, exceeding revenue forecasts.
Jain Rachit, Schrodinger CFO, sells $21k in SDGR stock By Investing.com
Schrodinger, Inc.'s CFO, Jain Rachit, sold 1,631 shares of common stock for a total of $21,033 on March 5, 2026. This sale was conducted under a pre-arranged trading plan to cover tax obligations from vested restricted stock units. Despite recent stock volatility, the company recently reported strong Q4 and full-year 2025 earnings, exceeding revenue forecasts.
Schrodinger (NASDAQ:SDGR) Insider Karen Akinsanya Sells 1,366 Shares
Karen Akinsanya, an insider at Schrodinger (NASDAQ:SDGR), sold 1,366 shares of the company's stock for a total of $17,621.40. This sale was part of a larger cluster of executive sales between March 4-6, including the CEO and CFO, which could indicate near-term selling pressure. Despite beating quarterly EPS and revenue estimates, Schrodinger remains unprofitable, and shares are trading below their 50- and 200-day moving averages.
Schrodinger (NASDAQ:SDGR) Insider Sells $16,653.00 in Stock
Robert Lorne Abel, an insider at Schrodinger (NASDAQ:SDGR), sold 1,300 shares of the company's stock valued at $16,653.00, reducing his direct ownership by 2.27%. This follows another sale in February and is part of a series of insider sales by multiple executives between March 4-6, contributing to potential near-term selling pressure on the stock. Despite beating quarterly earnings estimates, Schrodinger remains unprofitable, and analysts hold a mixed "Hold" consensus on the stock.
Schrodinger (NASDAQ:SDGR) EVP Kenneth Patrick Lorton Sells 1,222 Shares
Schrodinger EVP Kenneth Patrick Lorton sold 1,222 shares of SDGR stock for $15,763.80, reducing his stake by 1.35%. This sale is part of a cluster of insider sales from March 4-6, including the CEO and CFO, which could indicate near-term selling pressure. Despite beating Q4 earnings expectations, the company remains unprofitable, and analysts hold an average "Hold" rating with a consensus price target of $21.75.
Schrodinger, Inc. $SDGR Shares Sold by ARK Investment Management LLC
ARK Investment Management LLC reduced its stake in Schrodinger, Inc. ($SDGR) by 4.4% in the third quarter by selling 86,584 shares, though it still holds 2.54% of the company. Despite Schrodinger beating Q1 EPS and revenue estimates, analysts forecast a negative EPS for the current fiscal year, and the company remains unprofitable. Institutional investors collectively own 79.05% of Schrodinger's stock.
[144] Schrodinger, Inc. SEC Filing
Schrodinger, Inc. (SDGR) has filed a Form 144 Notice of Proposed Sale of Securities, indicating the planned sale of 3,125 shares of Common Stock as a stock bonus on March 4, 2026. The filing also reports a previous sale of 1,230 shares on February 9, 2026, and states that 64,500,510 shares are outstanding as of March 4, 2026. The SEC filing outlines details regarding the acquisition and proposed sale of these securities.
Vanguard Group Inc. Has $127.16 Million Holdings in Schrodinger, Inc. $SDGR
Vanguard Group Inc. reduced its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 4.2% in the third quarter, now holding 6,339,077 shares valued at $127.16 million. Despite beating quarterly revenue and EPS estimates, Schrodinger remains unprofitable, with analysts forecasting a negative EPS for the current fiscal year. Analyst sentiment is mixed, with an average "Hold" rating and a target price of $21.75.
Schrodinger (SDGR) executive receives new RSUs and stock option grant
Robert Lorne Abel, an executive at Schrodinger, Inc. (SDGR), has received new equity awards comprising a stock option for 34,250 shares and restricted stock units (RSUs) totaling 37,812 shares. These awards include 17,130 new time-based RSUs vesting over four years and 20,682 performance-based RSUs from previous grants whose performance metrics were recently certified. The vesting of all awards is contingent upon his continued service with the company.
Schrodinger (NASDAQ: SDGR) CEO gets options, sells shares under 10b5-1
Schrödinger, Inc. President & CEO Farid Ramy reported receiving a stock option for 112,500 shares and multiple grants of common stock and performance-based restricted stock units. On the same date, he sold 5,560 shares of common stock at a weighted average price of $11.8977 under a pre-arranged Rule 10b5-1 plan to cover tax liabilities from PRSU vesting. The sales were not discretionary and were executed to fulfill tax obligations.
Schrodinger, Inc. (NASDAQ:SDGR) Given Average Rating of "Hold" by Brokerages
Schrodinger, Inc. (NASDAQ:SDGR) has received an average "Hold" rating from nine brokerages, with an average 1-year target price of $21.75. The company recently reported quarterly EPS of $0.44 and revenue of $87.2 million, surpassing estimates, but remains unprofitable. Institutional ownership of SDGR stands at 79.05%.
[144] Schrodinger, Inc. SEC Filing
Schrodinger, Inc. (SDGR) has filed a Form 144 Notice of Proposed Sale of Securities, indicating the planned sale of 5,560 shares of common stock at an aggregate market value of $66,151.21. The securities were acquired through restricted stock vesting on February 27, 2026, and are expected to be sold around March 2, 2026, via Fidelity Brokerage Services LLC on NASDAQ. This filing provides transparency regarding the potential sale of securities by an insider or affiliate of the company.
Schrodinger (NASDAQ: SDGR) EVP granted stock options and RSU awards
Schrodinger, Inc.'s EVP, CLO & CPO, Yvonne Tran, was granted stock options and Restricted Stock Units (RSUs) on March 2, 2026, as detailed in a Form 4 SEC filing. She received options for 34,250 shares and 17,130 time-based RSUs, both vesting over several years subject to continued service. Additionally, 13,788 previously granted performance-based RSUs had their performance metrics certified and will vest upon the company's 2026 10-K filing.
Schrodinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth
Schrodinger Inc. (NASDAQ: SDGR) reported strong fourth-quarter and full-year 2025 results, demonstrating robust revenue growth and a shift towards a more predictable licensing model. The company's full-year revenue increased by 23.3% to $255.9 million, while drug discovery revenue more than doubled. Schrodinger also bounced to profitability in Q4 FY25 with a net income of $32.5 million and issued optimistic 2026 guidance for both software and drug discovery revenue.
Schrödinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth
Schrödinger, Inc. (SDGR) reported strong fourth-quarter and full-year 2025 results, with full-year revenue up 23.3% to $255.9 million, driven by doubling drug discovery revenue and a 10.6% increase in software revenue. The company is accelerating its transition to a licensing model for more predictable revenue and achieved profitability in Q4 FY25. Schrödinger also issued optimistic 2026 guidance for its software and drug discovery segments.
Schrodinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth
Schrodinger Inc. (SDGR) reported strong fourth-quarter and full-year 2025 results, with full-year revenue up 23.3% to $255.9 million. The company is accelerating its shift to a licensing model for more predictable revenue and achieved profitability in Q4 FY25, reporting a net income of $32.5 million. Schrodinger also provided impressive 2026 guidance, projecting software revenue between $218 and $228 million and drug discovery revenue between $55 million and $65 million.
Schrödinger (SDGR) Valuation After 2025 Results And Shift To Hosted Licensing Model
Schrödinger (SDGR) reported 2025 revenues of US$255.87 million and a net loss of US$103.27 million, alongside a shift to a hosted licensing model. Despite a significant share price decline, valuation models suggest the stock is undervalued, with a fair value of $43.20 (Simply Wall St narrative) and $52.92 (DCF model), compared to a recent close of $12.06. This undervaluation hinges on future clinical success and disciplined cash use, with a caveat that these forecasts rely on long-range projections while the company is still unprofitable.
Does Schrödinger’s 2025 Revenue Surge And Narrower Loss Reshape The Bull Case For SDGR?
Schrödinger, Inc. reported strong 2025 results with US$255.87 million in revenue and a reduced net loss of US$103.27 million, suggesting effective scaling and cost control. This performance, coupled with a significant collaboration with Lilly’s TuneLab, reinforces the company's investment narrative for its AI-powered drug discovery platform. While the results alleviate some concerns about profitability, dependence on milestone and royalty revenue remains a key risk.
11 Best Cancer Stocks to Invest In Now
This article highlights Schrödinger, Inc. (NASDAQ: SDGR) as one of the top cancer stocks to invest in. The company reported strong Q4 and full-year 2025 results, with significant growth in drug discovery revenue and a move towards profitability in Q4 2025. Schrödinger also provided positive guidance for 2026, driven by its physics-based software platform for drug development.
Does Schrödinger’s 2025 Revenue Surge And Narrower Loss Reshape The Bull Case For SDGR?
Schrödinger, Inc. reported strong full-year 2025 results with a significant revenue increase to US$255.87 million and a reduced net loss of US$103.27 million, suggesting effective scaling and cost control. This performance, alongside recent collaborations like the one with Lilly’s TuneLab, reinforces the potential of its physics-based and AI drug discovery platform. Despite these positive developments, the company still faces challenges related to ongoing losses and a reliance on milestone and royalty revenues.
